Dyslipidemia in Type 2 Diabetes (0767-034)

Trial Profile

Dyslipidemia in Type 2 Diabetes (0767-034)

Phase of Trial: Phase III

Latest Information Update: 15 Jul 2014

At a glance

  • Drugs MK 0767 (Primary) ; Glipizide; Pioglitazone
  • Indications Dyslipidaemias; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 02 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top